Soluble Guanylate Cyclase sGC or EC 4.6.1.2 Pipeline Review, H1 2018
Summary
Soluble Guanylate Cyclase sGC or EC 4.6.1.2 pipeline Target constitutes close to 27 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Soluble Guanylate Cyclase Pipeline Review, H1 2018, outlays comprehensive information on the Soluble Guanylate Cyclase sGC or EC 4.6.1.2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Soluble Guanylate Cyclase sGC or EC 4.6.1.2 Soluble guanylyl cyclase sGC is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 3, 13 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Ophthalmology, Central Nervous System, Gastrointestinal, Hematological Disorders, Immunology, Infectious Disease, Oncology, Respiratory, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones and Toxicology which include indications Ocular Hypertension, Glaucoma, Diabetic Nephropathy, Pulmonary Hypertension, Sickle Cell Disease, Tinea pedis Athlete Foot, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Carotid Artery Stenosis, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease Chronic Renal Failure, Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Neuropathic Pain, Diastolic Heart Failure, Duchenne Muscular Dystrophy, Esophageal Achalasia, Hypertension, Inflammation, Ischemic Stroke, Liver Diseases, Lung Infections, Onychomycosis Tinea Unguium, OpenAngle Glaucoma, Optic Neuropathy, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Arterial Hypertension, Stroke, Systemic Sclerosis Scleroderma, Systolic Heart Failure, Vascular Dementias and Wounds.
Furthermore, this report also reviews key players involved in Soluble Guanylate Cyclase sGC or EC 4.6.1.2 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase sGC or EC 4.6.1.2
The report reviews Soluble Guanylate Cyclase sGC or EC 4.6.1.2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Soluble Guanylate Cyclase sGC or EC 4.6.1.2 targeted therapeutics and enlists all their major and minor projects
The report assesses Soluble Guanylate Cyclase sGC or EC 4.6.1.2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Soluble Guanylate Cyclase sGC or EC 4.6.1.2 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase sGC or EC 4.6.1.2
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase sGC or EC 4.6.1.2 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Original Article: Soluble Guanylate Cyclase sGC or EC 4.6.1.2 Pipeline Review, H1 2018 [Report Updated: 28022018] Prices from USD $3500
NEXT ARTICLE